IP Library Granted Patent US 7,550,450
Granted Patent B2
US 7,550,450 · App. 11/862,153 · Granted Jun 23, 2009

Prostate cancer treatment

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,550,450
App. No.
11/862,153
Granted
Jun 23, 2009
Kind
B2
Abstract

The instant invention provides potent antiandrogen compounds, such as 3β-acetoxyandrost-1,5-diene-17-ethylene ketal and 3β-hydroxyandrost-1,5-diene-17-ethylene ketal, and methods for their use in the prevention and treatment of biological conditions mediated by androgen receptors. Thus, for example, compounds of the invention are useful in the prevention and treatment of prostrate cancer. Furthermore, it has been discovered that compounds of the invention are useful in the prevention and treatment of androgen-independent cancers such as androgen-independent prostrate cancer. Finally, inventive compounds may be used to treat antiandrogen induced withdrawal syndrome.

Claims (23)

1. A method to treat prostate cancer in a subject in need thereof, comprising administering an effective amount of a compound having the structure

wherein

E is —C(O)— or —CR 5 R 6 —;

G is —CR 3 R 4 —;

K is —CR 1 R 2 —;

R 1 is —OR 11

R 2 is —H, lower alkyl or substituted lower alkyl;

R 3 and R 5 independently are —H, —OH or lower alkyl;

R 4 and R 6 independently are —H or lower alkyl;

R 11 is —H, alkyl or substituted alkyl, —C(O)—R 12 , —S(O) 0-2 —R 12 or —C(O)—OR 12 ;

R 12 is —H, alkyl or substituted alkyl;

R is —OH or unsubstituted lower alkoxy;

R′ is —F or unsubstituted lower alkyl;

n is 0 or 1; and

n′ is 0 or 1.

2. The method of claim 1 wherein the compound has the structure

wherein R 2 is —H;

R 3 and R 5 are independently —H or —OH;

R 4 and R 6 are —H;

R 11 is —H, alkyl or —C(O)—R 12 .

3. The method of claim 2

wherein R 1 is —OH or —OC(O)—R 12 .

4. The method of claim 3 wherein the compound has the structure

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 8, 2021
From: NEURMEDIX, INC.
To: NEURMEDIX, LLC
Reel/Frame 057116/0336 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 8, 2021
From: NEURMEDIX, LLC
To: NEURMEDIX, INC.
Reel/Frame 057116/0362 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 8, 2021
From: NEURMEDIX, INC.
To: BIOVIE INC.
Reel/Frame 057116/0451 →
CHANGE OF NAME Recorded Nov 2, 2012
From: HARBOR BIOSCIENCES, INC.
To: HARBOR DIVERSIFIED, INC.
Reel/Frame 029227/0929 →
CHANGE OF NAME Recorded Mar 11, 2010
From: HOLLIS-EDEN PHARMACEUTICALS, INC.
To: HARBOR BIOSCIENCES, INC.
Reel/Frame 024066/0325 →